A Phase I/IIa Randomized Trial Evaluating the Safety and Efficacy of SNK01 Plus Pembrolizumab in Patients with Stage IV Non–Small Cell Lung Cancer

PURPOSE: The aim of this study is to evaluate the safety and efficacy of ex vivo activated and expanded natural killer (NK) cell therapy (SNK01) plus pembrolizumab in a randomized phase I/IIa clinical trial. MATERIALS AND METHODS: Overall, 18 patients with advanced non–small cell lung cancer (NSCLC)...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Eo Jin, Cho, Yong-Hee, Kim, Dong Ha, Ko, Dae-Hyun, Do, Eun-Ju, Kim, Sang-Yeob, Kim, Yong Man, Jung, Jae Seob, Kang, Yoonmi, Ji, Wonjun, Choi, Myeong Geun, Lee, Jae Cheol, Rho, Jin Kyung, Choi, Chang-Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9582480/
https://www.ncbi.nlm.nih.gov/pubmed/34856706
http://dx.doi.org/10.4143/crt.2021.986

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9582480/
https://www.ncbi.nlm.nih.gov/pubmed/34856706
http://dx.doi.org/10.4143/crt.2021.986

Ejemplares similares